HomeEXECUTIVESArvin Yang, MD, PhD Appointed Chief Medical Officer of Pheon Therapeutics

Arvin Yang, MD, PhD Appointed Chief Medical Officer of Pheon Therapeutics

Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Dr. Arvin Yang joins Pheon with over a decade of experience in leading therapeutic oncology products through early-stage clinical development, and late-stage global registration trials at both Bristol Myers Squibb and Mersana Therapeutics.

Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: “As a seasoned Chief Medical Officer, Dr. Yang’s extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company. His deep knowledge of oncology clinical development will be invaluable as we advance our first-in-class ADCs for the treatment of solid tumors.”

Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors. We are now preparing to transition into clinical development and are working diligently to improve outcomes for patients facing hard-to-treat cancers.

At Mersana Therapeutics, Dr. Yang oversaw the clinical development of multiple novel assets in both early and late-stage global development. Prior to his work at Mersana, Dr. Yang spent over a decade at Bristol Myers Squibb, in a variety of leadership roles, making contributions that spanned all stages of the development process, from discovery through late-stage clinical trials and approvals. His work included generating clinical development plans and driving the approvals of nivolumab, ipilimumab, fedratinib, and luspatercept.

Dr. Yang earned his MD and PhD from Rutgers Robert Wood Johnson Medical School, training in internal medicine at Beth Israel Deaconess, Harvard Medical School, and in oncology at Memorial Sloan-Kettering Cancer Center. He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Dr John Parker will work closely with PeriGen's client base to optimize use of the company's analytics for patient care and research. He will also be instrumental in informing product development and regulatory affairs as PeriGen continues to expand its product suite and associated services.
“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.
Broken String Biosciences reports Gavin Burns will be responsible for building and optimizing the companys teams, processes, and systems.
“We are pleased to strengthen our Clinical Advisory Board and to welcome our new members,” commented Pierre Leurent, President, Aptar Digital Health. “Their broad medical expertise will allow us to have a deeper knowledge and expand our global vision of the clinical practice for multiple types of cancer.”
Dr Ronald Silverman will be responsible for leading the company's Medical Affairs organization, which includes end-to-end medical affairs across BD's business units, regions and central team. In this role, he will use medical insights and expertise to advance BD's pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD's in-market portfolio of products.

By using this website you agree to accept Medical Device News Magazine Privacy Policy